GlassScriptPhysician profile
Sara L Johnston
NPI 1740245638
$522.92
in general payments reported to CMS, 2019-2025
13 companies · $69.92 in 2025
The $69.92 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $63.14 · 2020: $27.01 · 2021: $78.54 · 2022: $46.26 · 2023: $178 · 2024: $60.06 · 2025: $69.92.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $308.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $307.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $151.75 | 2019-2025 | |
| Glaxosmithkline, LLC. | $78.61 | 2022-2025 | Bexsero, Shingrix, Penmenvy |
| Novo Nordisk INC | $77.99 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
| Astellas Pharma US INC | $49.53 | 2019-2024 | Veozah |
| Merck Sharp & Dohme LLC | $27.04 | 2021-2023 | Steglatro, Belsomra |
| Abbvie INC. | $24.89 | 2021 | |
| Lilly USA, LLC | $24.36 | 2021-2022 | |
| Procept Biorobotics Corporation | $17.50 | 2024 | Aquabeam System |
| Idorsia Pharmaceuticals US INC | $16.06 | 2023 | Quviviq |
| Astrazeneca Pharmaceuticals LP | $14.24 | 2020 | |
| Novartis Pharmaceuticals Corporation | $14.16 | 2025 | |
| Amgen INC. | $13.44 | 2023 | Otezla, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $13.35 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Johnston listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.